Inactivation of the p53 tumor suppressor pathway allows cell survival in times of stress and occurs in many human cancers; however, normal embryonic stem cells and some cancers such as neuroblastoma maintain wild-type human TP53 and mouse Trp53 (referred to collectively as p53 herein). Here we describe a miRNA, miR-380-5p, that represses p53 expression via a conserved sequence in the p53 3′ untranslated region (UTR). miR-380-5p is highly expressed in mouse embryonic stem cells and neuroblastomas, and high expression correlates with poor outcome in neuroblastomas with neuroblastoma derived v-myc myelocytomatosis viral-related oncogene (MYCN) amplification. miR-380 overexpression cooperates with activated HRAS oncoprotein to transform primary cells, block oncogene-induced senescence and form tumors in mice. Conversely, inhibition of endogenous miR-380-5p in embryonic stem or neuroblastoma cells results in induction of p53, and extensive apoptotic cell death. In vivo delivery of a miR-380-5p antagonist decreases tumor size in an orthotopic mouse model of neuroblastoma. We demonstrate a new mechanism of p53 regulation in cancer and stem cells and uncover a potential therapeutic target for neuroblastoma.
At a glance
- Coping with stress: multiple ways to activate p53. Oncogene 26, 1306–1316 (2007). &
- The P53 pathway: what questions remain to be explored? Cell Death Differ. 13, 1027–1036 (2006). , &
- Cancer genes and the pathways they control. Nat. Med. 10, 789–799 (2004). &
- TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 2157–2165 (2007). , , , &
- The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 7, 979–987 (2008). , , &
- Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323–1334 (2006). , &
- Restoration of p53 function leads to tumour regression in vivo . Nature 445, 661–665 (2007). et al.
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007). et al.
- The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 197, 93–98 (2003). et al.
- Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc. Natl. Acad. Sci. USA 99, 15632–15637 (2002). et al.
- Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14, 981–993 (2000). et al.
- p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following γ-irradiation. Oncogene 9, 1767–1773 (1994). , , , &
- Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849–852 (1993). et al.
- p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847–849 (1993). , , , &
- Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J. 16, 1381–1390 (1997). et al.
- Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17, 4657–4667 (1998). et al.
- p53 translational control: a new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Gene 395, 1–7 (2007). &
- Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat. Rev. Genet. 9, 831–842 (2008). &
- MicroRNAs and cancer: short RNAs go a long way. Cell 136, 586–591 (2009). &
- Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259–269 (2006). &
- MicroRNA targets in Drosophila . Genome Biol. 5, R1 (2003). et al.
- Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res. 35, 2333–2342 (2007). et al.
- Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436, 214–220 (2005). , &
- Experimental validation of miRNA targets. Methods 44, 47–54 (2008). et al.
- A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res. 14, 1741–1748 (2004). et al.
- The non-apoptotic role of p53 in neuronal biology: enlightening the dark side of the moon. EMBO Rep. 10, 576–583 (2009). &
- MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 23, 862–876 (2009). et al.
- A translation repressor element resides in the 3′ untranslated region of human p53 mRNA. Oncogene 18, 6419–6424 (1999). , &
- RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc. Natl. Acad. Sci. USA 100, 8354–8359 (2003). et al.
- Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 9, 493–505 (2007). et al.
- Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc. Natl. Acad. Sci. USA 105, 5402–5407 (2008). , , &
- MET and MYC cooperate in mammary tumorigenesis. Proc. Natl. Acad. Sci. USA 102, 4324–4329 (2005). , , &
- An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo . Nat. Genet. 33, 396–400 (2003). et al.
- Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 282, 1479–1486 (2007). et al.
- Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res. 61, 8–13 (2001). , , , &
- Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985–2995 (1997). , , , &
- Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 10, 1268–1274 (2008). et al.
- Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc. Natl. Acad. Sci. USA 104, 18682–18687 (2007). et al.
- Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 66, 8139–8146 (2006). et al.
- ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res. 68, 9735–9745 (2008). et al.
- Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res. 69, 547–553 (2009). et al.
- Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res. 37, 70–77 (2009). et al.
- Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 465, 175–181 (2010). et al.
- Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460, 1140–1144 (2009). et al.
- Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005–1017 (2009). et al.
- OncomiR addiction in an in vivo model of microRNA-21–induced pre-B-cell lymphoma. Nature advance online publication, doi:10.1038/nature09284 (8 August 2010). , &
- Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28, 341–347 (2010). et al.
- Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406–3415 (2003).
- Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J. Clin. Oncol. 24, 1546–1553 (2006). et al.
- A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA 12, 733–750 (2006). , &
- Supplementary Text and Figures (1M)
Supplementary Figures 1–6, Supplementary Table 1 and Supplementary Methods